Allegations against ARS Pharmaceuticals, Inc.: Schall Law Firm launches investigation and encourages affected investors to come forward

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims of violations of the securities laws on behalf of investors in ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ:SPRY).

The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose relevant information to investors. The FDA rejected the epinephrine nasal spray developed by ARS on September 19, 2023. The FDA’s Complete Response Letter (CRL) also asked the company for an additional day to review efficacy and safety. On this news, ARS shares fell nearly 55% in intraday trading on September 20, 2023.

If you are a shareholder who has suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You may also contact us through the firm’s website at www.schallfirm.com or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you will not be represented by counsel. If you choose to take no action, you may remain as an absent class member.

The Schall Law Firm represents investors throughout the world and specializes in securities class action litigation and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and professional rules.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm

View the original press release on accesswire.com.